Helping Singapore to flatten the curve is MiRXES, a homegrown biotechnology company co-founded by Dr. Zhou Lihan in 2014. Prior to manufacturing Covid-19 test kits, MiRXES specialises in the world’s ...

Showcasing this expertise is GASTROClear, the world’s first RNA-powered blood test for early detection of gastric cancer. The kit assesses the quantities of 12 microRNA biomarkers, allowing the ...

SINGAPORE, April 23, 2020 /PRNewswire/ -- MiRXES, a homegrown Singapore-based biotech, has received Provisional Authorisation from the Health Sciences Authority (HSA) Singapore, to supply the ...

SINGAPORE - Long before Covid-19 struck, local biotech company Mirxes had, for seven years, been developing polymerase chain reaction (PCR) tests to detect cancer. Read more at straitstimes.com.

Mainland China will become the largest single market for Singaporean diagnostics start-up Mirxes' core product, a stomach cancer detection kit that was key to the company's development, according ...

Mainland China will become the largest single market for Mirxes’ core product, a stomach cancer detection kit that was key to the company’s development, according to Zhou Lihan, its CEO and co ...

Mirxes Holding Company Ltd. raised $50 million in a series D funding round to expand its cancer early detection blood tests, including its lead product stomach cancer blood test Gastroclear, in the ...

MiRXES, an emerging global biotechnology company based in Singapore, wanted to raise awareness of stomach cancerand the importance of early detection in successful treatment. The Objectives Drive ...